Information on this company is supplied by EMIS which is part of Euromoney Institutional Investor plc, one of Europe's largest publishers and a constituent of the FTSE 250 index.
Full name: Amgen Inc. (Amgen Inc.)
Legal Form: Public Limited Company
Operational Status: Operational
Incorporation Date: 1980
Aranesp (darbepoetin alfa), Enbrel(etanercept), EPOGEN (Epoetin alfa), Neulasta (pegfilgrastim), NEUPOGEN (Filgrastim), Nplate (romiplostim), Prolia (denosumab), Sensipar (cinacalcet), Vectibix (panitumumab), XGEVA (denosumab)More
Amgen discovers, develops, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing novel medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses.More
|Company Tear Sheet|
|NAICS Industry Classification||✓||✕|
|Share Price information||✓||✕|
|Subsidiaries and Affiliates||✓||✕|
|Key Financial Highlights||✓||✕|
|Financial Performance Charts||✓||✕|
|Latest M&A and ECM Deals||✓||✕|
|EMIS Credit Analytics|
|EMIS Benchmark Score||✓||✕|
- or -
EMIS company profiles are part of a larger information service that combines company, industry and country data and analysis for over 120 emerging markets on a unique information platform.
If you need broad and deep coverage of one or many countries, you may be interested in subscribing. Request a demonstration of our full service and one of our account managers will be in touch.